Open Access

ARTICLE

Mesenchymal stem cells transplantation attenuates experimentally induced brain injury after neonatal hypoxia by different two routes of administrations

Nesrine EBRAHIM¹, Eman EHSAN², Eman Abd EL GHANY², Dina SABRY³, Ashraf SHAMAA⁴

1 Histology and Cell Biology Department, Faculty of Medicine, Benha University, Benha, Egypt
2 Pediatrics Department, Faculty of Medicine, Cairo University, Giza, Egypt
3 Medical Biochemistry and molecular biology Department, Faculty of Medicine, Cairo University, Giza, Egypt
4 Surgical and Radiology Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egyp

* Address correspondence to: Nesrine Ebrahim,

BIOCELL 2019, 43(1), 21-28. https://doi.org/10.32604/biocell.2019.06111

Abstract

The neonatal hypoxic–ischemic encephalopathy (HIE) is an important cause of neurological morbidity and mortality in neonates. Cell therapy is considered a promising method for treating severe neurological disorders such as this one. Stem cells have the capacity for self-renewal and differentiation into certain cell lineages. The present study was aimed to find out the most beneficial route of bone marrow-derived mesenchymal stem cells (BMSCs) administration for the attenuation of experimentally induced HIE in neonatal rats. Sixty neonatal rats were divided randomly into four groups. Group 1: control group. Group 2: rats were exposed to bilateral ligation of cephalic arteries. Group 3: rats were exposed to bilateral ligation of cephalic arteries and then underwent intravenous (IV) BMSC injection. Group 4: rats were exposed to bilateral ligation of cephalic arteries and then underwent intracerebroventricular (ICV) BMSC injection. The animals were evaluated by (a) neurobehavioral tests; (b) histopathology, i.e., histological and immunohistochemical studies; and (3) gene expression studies. The BMSC treated groups (3 and 4) showed improvement in neurobehavioral tests, histopathological studies, and gene expression, as compared to non-injected lesioned rats (Group 2) with better improvement in Group 4 (ICV injections) than in Group 3 (IV injections).

---

Keywords

---

Citations